Dong-A ST Co., Ltd. (170900.KS)
KRW 47300.0
(-1.77%)
KRW 47300.0
(-1.77%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 193.95 Billion KRW | 307.44% |
| 2022 | 47.6 Billion KRW | -55.08% |
| 2021 | 105.97 Billion KRW | 81.18% |
| 2020 | 58.49 Billion KRW | 427.1% |
| 2019 | -17.88 Billion KRW | -124.44% |
| 2018 | -7.96 Billion KRW | 26.52% |
| 2017 | -10.84 Billion KRW | -259.93% |
| 2016 | 6.77 Billion KRW | -91.13% |
| 2015 | 76.4 Billion KRW | -50.8% |
| 2014 | 155.28 Billion KRW | -30.32% |
| 2013 | 222.85 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 321.64 Billion KRW | 48.74% |
| 2024 Q1 | 216.25 Billion KRW | 11.5% |
| 2023 Q4 | 193.95 Billion KRW | 49.03% |
| 2023 Q1 | 93.66 Billion KRW | 96.76% |
| 2023 FY | 193.95 Billion KRW | 307.44% |
| 2023 Q3 | 130.14 Billion KRW | 20.16% |
| 2023 Q2 | 108.3 Billion KRW | 15.63% |
| 2022 FY | 47.6 Billion KRW | -55.08% |
| 2022 Q1 | 153.71 Billion KRW | 45.05% |
| 2022 Q2 | 160.49 Billion KRW | 4.41% |
| 2022 Q4 | 47.6 Billion KRW | -68.78% |
| 2022 Q3 | 152.48 Billion KRW | -4.99% |
| 2021 Q4 | 105.97 Billion KRW | 15.37% |
| 2021 Q2 | 25.98 Billion KRW | 824.69% |
| 2021 FY | 105.97 Billion KRW | 81.18% |
| 2021 Q1 | -3.58 Billion KRW | -106.13% |
| 2021 Q3 | 91.85 Billion KRW | 253.52% |
| 2020 Q1 | -31.42 Billion KRW | -75.71% |
| 2020 FY | 58.49 Billion KRW | 427.1% |
| 2020 Q4 | 58.49 Billion KRW | 330.45% |
| 2020 Q3 | -25.38 Billion KRW | 27.03% |
| 2020 Q2 | -34.78 Billion KRW | -10.7% |
| 2019 Q3 | -21.49 Billion KRW | -434.94% |
| 2019 Q4 | -17.88 Billion KRW | 16.79% |
| 2019 Q1 | 9.04 Billion KRW | 213.57% |
| 2019 FY | -17.88 Billion KRW | -124.44% |
| 2019 Q2 | 6.41 Billion KRW | -29.09% |
| 2018 FY | -7.96 Billion KRW | 26.52% |
| 2018 Q4 | -7.96 Billion KRW | -172.83% |
| 2018 Q3 | 10.94 Billion KRW | 57.61% |
| 2018 Q2 | 6.94 Billion KRW | -76.71% |
| 2018 Q1 | 29.81 Billion KRW | 374.93% |
| 2017 Q1 | -2.77 Billion KRW | -140.91% |
| 2017 Q2 | -17.14 Billion KRW | -517.95% |
| 2017 Q3 | -14.54 Billion KRW | 15.15% |
| 2017 Q4 | -10.84 Billion KRW | 25.45% |
| 2017 FY | -10.84 Billion KRW | -259.93% |
| 2016 Q2 | 47.22 Billion KRW | 129.35% |
| 2016 FY | 6.77 Billion KRW | -91.13% |
| 2016 Q4 | 6.77 Billion KRW | -57.62% |
| 2016 Q3 | 15.99 Billion KRW | -66.12% |
| 2016 Q1 | 20.59 Billion KRW | -73.05% |
| 2015 Q4 | 76.4 Billion KRW | -39.99% |
| 2015 FY | 76.4 Billion KRW | -50.8% |
| 2015 Q3 | 127.32 Billion KRW | -2.45% |
| 2015 Q2 | 130.51 Billion KRW | -17.89% |
| 2015 Q1 | 158.95 Billion KRW | 2.36% |
| 2014 FY | 155.28 Billion KRW | -30.32% |
| 2014 Q1 | 189.63 Billion KRW | -14.91% |
| 2014 Q2 | 171.3 Billion KRW | -9.67% |
| 2014 Q3 | 150.85 Billion KRW | -11.94% |
| 2014 Q4 | 155.28 Billion KRW | 2.94% |
| 2013 Q2 | 200.42 Billion KRW | 0.0% |
| 2013 Q3 | 199.2 Billion KRW | -0.61% |
| 2013 Q4 | 222.85 Billion KRW | 11.88% |
| 2013 FY | 222.85 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -2103.42% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 66.094% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -156.295% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | -17.844% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 37.611% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | -672.453% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | -866.266% |
| Yuhan Corporation | -69.18 Billion KRW | 380.33% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 5362.081% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 698.024% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | -426.505% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | -135.034% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | -66.858% |
| CKD Bio Corp. | 143.29 Billion KRW | -35.349% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -2103.42% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 3.481% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | -13.459% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -25.639% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -8148.587% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | -743.211% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | -225.016% |
| HANDOK Inc. | 283.45 Billion KRW | 31.576% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -2103.42% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | -22.523% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 45.851% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -25.639% |
| Yuhan Corporation | -69.18 Billion KRW | 380.33% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | -42.619% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 62.55% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -164920.145% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 54.806% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -25.639% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 54.132% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 221.335% |
| JW Holdings Corporation | 480.68 Billion KRW | 59.651% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | -10.846% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | -273.164% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -8148.587% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | -67.102% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -1080.818% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 533.563% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 906.055% |
| Boryung Corporation | 187.72 Billion KRW | -3.315% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 369.975% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -156.295% |
| JW Lifescience Corporation | 26.09 Billion KRW | -643.371% |